Alvotech – NASDAQ:ALVO
Alvotech stock price today
$8.8
-3.86
-30.54%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Alvotech stock price monthly change
+4.28%
month
Alvotech stock price quarterly change
+4.28%
quarter
Alvotech stock price yearly change
+12.32%
year
Alvotech key metrics
Market Cap | 3.74B |
Enterprise value | 3.35B |
P/E | -5.21 |
EV/Sales | 39.75 |
EV/EBITDA | -6.24 |
Price/Sales | 31.00 |
Price/Book | -4.63 |
PEG ratio | N/A |
EPS | -1.83 |
Revenue | 88M |
EBITDA | -308.95M |
Income | -494.28M |
Revenue Q/Q | -21.64% |
Revenue Y/Y | -10.60% |
Profit margin | -693.98% |
Oper. margin | -374.39% |
Gross margin | 7.22% |
EBIT margin | -374.39% |
EBITDA margin | -351.09% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlvotech stock price history
Alvotech stock forecast
Alvotech financial statements
| Jun 2023 | 4.39M | 189.32M | 4311.68% |
|---|---|---|---|
| Aug 2023 | 17.78M | -188.32M | -1058.63% |
| Dec 2023 | 53.39M | -276.55M | -517.99% |
| Mar 2024 | 12.43M | -218.72M | -1759.69% |
| Dec 2023 | 53.39M | -276.55M | -517.99% |
|---|---|---|---|
| Mar 2024 | 12.43M | -218.72M | -1759.69% |
| Sep 2025 | 20.88M | 26.94M | 129.04% |
| Dec 2025 | 22.77M | 21.07M | 92.57% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 910662000 | 1.38B | 152.55% |
|---|---|---|---|
| Aug 2023 | 958819000 | 1.61B | 168.92% |
| Dec 2023 | 950090000 | 1.88B | 198.15% |
| Mar 2024 | 1060637000 | 1.71B | 162.12% |
| Jun 2023 | -41.87M | -11.35M | -2.73M |
|---|---|---|---|
| Aug 2023 | -117.02M | -10.65M | 136.20M |
| Dec 2023 | -67.16M | -10.46M | 20.66M |
| Mar 2024 | -75.40M | -3.48M | 133.18M |
Alvotech alternative data
| Aug 2023 | 917 |
|---|---|
| Sep 2023 | 917 |
| Oct 2023 | 917 |
| Nov 2023 | 917 |
| Dec 2023 | 917 |
| Jan 2024 | 917 |
| Feb 2024 | 917 |
| Mar 2024 | 917 |
| Apr 2024 | 917 |
| May 2024 | 999 |
| Jun 2024 | 999 |
| Jul 2024 | 999 |
Alvotech other data
5.98%
-14.04%
of ALVO is owned by hedge funds
5.60M
-13.14M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 22 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 29 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 31 Aug 2023 | Q2 2023 Earnings Call Transcript |
Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
Top 4 Immunology Stocks Poised For Growth In 2025
Teva Pharmaceutical: Buy This Bargain Before It's Gone
Fuji Pharma: High Scope For Growth In U.S. Foray, Biosimilars, And Women's Health Drugs
Alvotech: Biosimilar Specialist Targeting Lucrative Markets
Competition Coming For AbbVie's Blockbuster Humira
-
What's the price of Alvotech stock today?
One share of Alvotech stock can currently be purchased for approximately $8.8.
-
When is Alvotech's next earnings date?
Unfortunately, Alvotech's (ALVO) next earnings date is currently unknown.
-
Does Alvotech pay dividends?
No, Alvotech does not pay dividends.
-
How much money does Alvotech make?
Alvotech has a market capitalization of 3.74B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 10.12% to 91.43M US dollars.
-
What is Alvotech's stock symbol?
Alvotech is traded on the NASDAQ under the ticker symbol "ALVO".
-
What is Alvotech's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Alvotech?
Shares of Alvotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Alvotech have?
As Jul 2024, Alvotech employs 999 workers, which is 9% more then previous quarter.
-
When Alvotech went public?
Alvotech is publicly traded company for more then 3 years since IPO on 16 Jun 2022.
-
What is Alvotech's official website?
The official website for Alvotech is alvotech.com.
-
How can i contact Alvotech?
Alvotech can be reached via phone at +354 422 4500.
Alvotech company profile:
Alvotech
alvotech.comExchange:
NASDAQ
Full time employees:
999
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Saemundargata 15-19
Reykjavik, 102
Reykjavik, 102
CIK: 0001898416
ISIN: LU2458332611
CUSIP: L01800108
